Thomas F Whayne

Summary

Affiliation: University of Kentucky
Country: USA

Publications

  1. ncbi Ischemic heart disease and the Mediterranean diet
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Curr Cardiol Rep 16:491. 2014
  2. doi Assessment of low-density lipoprotein targets
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Angiology 64:411-6. 2013
  3. ncbi Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH Trial
    Thomas F Whayne
    Divisions of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Hematol Agents Med Chem 9:269-76. 2011
  4. doi Nutrition and the healthy heart with an exercise boost
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, 40536 0200, USA
    Can J Physiol Pharmacol 90:967-76. 2012
  5. doi Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Lexington, 40536, USA
    Angiology 62:415-21. 2011
  6. ncbi [Problems with statins and the marketing of these medications]
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Rev Med Chil 138:511-4. 2010
  7. doi What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Ther 28:106-23. 2010
  8. ncbi Problems with the new Adult Treatment Panel III guidelines
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Division of Cardiovascular Medicine, Lexington, KY 40536 0284, USA
    Prev Cardiol 5:91. 2002
  9. ncbi High-density lipoprotein cholesterol: current perspective for clinicians
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536, USA
    Angiology 60:644-9. 2009
  10. ncbi Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population
    Thomas F Whayne
    Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, 326 Wethington Building, 900 South Limestone, Lexington, KY 40536 0200, USA
    Indian Heart J 59:218-25. 2007

Collaborators

Detail Information

Publications17

  1. ncbi Ischemic heart disease and the Mediterranean diet
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone Street, Lexington, KY, 40536 0200, USA
    Curr Cardiol Rep 16:491. 2014
    ..Benefit also extends to other noncommunicable diseases with a decrease in cancer, Parkinson's disease, and Alzheimer's disease. Further quantitation of benefit and understanding of mechanisms involved in dietary benefit is essential...
  2. doi Assessment of low-density lipoprotein targets
    Thomas F Whayne
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Angiology 64:411-6. 2013
    ..A strategy of LDL-C reduction in no way interferes with increased understanding of the complexities of atherosclerosis and new approaches to CV disease prevention as they become supported by outcomes studies...
  3. ncbi Optimal medical therapy for coronary artery disease in 2011 - perspectives from the STICH Trial
    Thomas F Whayne
    Divisions of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Hematol Agents Med Chem 9:269-76. 2011
    ..Continued collaboration between cardiologists concentrating on medical approaches with interventionists and cardiac surgeons (heart team approach) is essential for optimal management for each individual patient. ..
  4. doi Nutrition and the healthy heart with an exercise boost
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, 40536 0200, USA
    Can J Physiol Pharmacol 90:967-76. 2012
    ..Antioxidants, endogenous or exogenous, have received increased interest and appear to play a favorable nutritional role. CV health starts with good nutrition...
  5. doi Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Lexington, 40536, USA
    Angiology 62:415-21. 2011
    ..The occurrence of the most serious complication of myopathy-rhabdomyolysis-is very rare, but awareness of the problem, risks, and prevention are essential...
  6. ncbi [Problems with statins and the marketing of these medications]
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536 0200, USA
    Rev Med Chil 138:511-4. 2010
    ..This actually occurs with any statin, a decrease also enhanced by ezetimibe. Statins have benefited the lives of our patients but, as with any treatment, the physician needs to look critically at all the problems and claims made...
  7. doi What should medical practitioners know about the role of alternative medicines in cardiovascular disease management?
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, KY, USA
    Cardiovasc Ther 28:106-23. 2010
    ..The result is that a number of these alternative medications will then interact with conventional CV medications, many times unfavorably...
  8. ncbi Problems with the new Adult Treatment Panel III guidelines
    Thomas F Whayne
    University of Kentucky, Gill Heart Institute, Division of Cardiovascular Medicine, Lexington, KY 40536 0284, USA
    Prev Cardiol 5:91. 2002
  9. ncbi High-density lipoprotein cholesterol: current perspective for clinicians
    Thomas F Whayne
    Gill Heart Institute, University of Kentucky, Lexington, Kentucky 40536, USA
    Angiology 60:644-9. 2009
    ..High-density lipoprotein cholesterol may play an important role in improving cardiovascular risk in the 60% of patients who do not receive cardiovascular mortality/morbidity benefit from low-density lipoproteins reduction by statins...
  10. ncbi Evaluation critique of state of the art dyslipidemia management in general and with a special emphasis on the Indian population
    Thomas F Whayne
    Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, 326 Wethington Building, 900 South Limestone, Lexington, KY 40536 0200, USA
    Indian Heart J 59:218-25. 2007
    ..Future treatments undoubtedly will involve genetics, but for now, aggressive medication use can favorably modify risk although not eliminate it...
  11. ncbi Current evidence for antithrombotic therapy after peripheral vascular interventions
    Sibu P Saha
    Division of Cardiothoracic Surgery, Gill Heart Institute, University of Kentucky, Lexington, KY 40536 0200, USA
    Curr Vasc Pharmacol 11:507-13. 2013
    ..Available medications remain in a state of flux and new oral direct thrombin and Factor Xa inhibitors may also find a place as clinical evidence-based medicine accumulates. ..
  12. ncbi Synopsis of an epidemiologic study of a Kentucky county in the Coronary Valley
    Vivian M Abascal
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 326 Wethington Building, 900 South Limestone, Lexington, KY 40536 0200, USA
    J Ky Med Assoc 106:527-31. 2008
    ..These findings may explain the high prevalence of cardiovascular (CV) disease in general and coronary heart disease (CHD) in particular, in parts of rural Appalachia even without the presence of significantly elevated cholesterol levels...
  13. ncbi Cardiovascular care: a challenge for Kentucky
    Sibu P Saha
    Gill Heart Institute, 326 Wethington Building, 900 South Limestone Street, Lexington, KY 40536 0200, USA
    J Ky Med Assoc 107:295-7. 2009
    ..Treating CV disease is clearly not enough; lifestyle habits need to be changed before CV disease develops...
  14. pmc Evidence-based management of carotid artery disease
    Sibu P Saha
    Gill Heart Institute and the Divisions of Cardiothoracic Surgery and Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA
    Int J Angiol 19:e21-4. 2010
    ..A medical-surgical team approach is now greatly contributing to the avoidance of stroke and its devastation...
  15. ncbi Current management of peripheral vascular disease: where is the evidence?
    Sibu P Saha
    Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY 40536, USA
    Cardiovasc Hematol Agents Med Chem 9:128-36. 2011
    ..It has been shown that these patients are undertreated in spite of their high cardiovascular risk. It is mandatory that they receive the same intensive treatment of risk factors as that given to coronary heart disease patients...
  16. doi Current treatment of heart failure in the USA
    Charles R Salters
    The University of Kentucky, 740 South Limestone Street, J525 Kentucky Clinic, Lexington, KY 40536 0284, USA
    Expert Rev Cardiovasc Ther 8:279-90. 2010
    ..It is the aim of this review to describe the framework for approaching heart failure patients so that the physician can provide the most appropriate therapies at each stage of the disease...
  17. doi Nonprescription statins: not ready for prime time
    Thomas F Whayne
    Am J Cardiol 101:745-6; author reply 746. 2008